Arthritis Research & Therapy

official impact factor 4.36
Search for
Advanced search
Arthritis Research & Therapy
Tools
Share this article

This article is part of the supplement: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor

Highly Access

Biology of RANK, RANKL, and osteoprotegerin

Brendan F Boyce* and Lianping Xing

Arthritis Research & Therapy 2007, 9(Suppl 1):S1 doi:10.1186/ar2165

Accesses  

  • Last 30 days: 263 accesses
  • Last 365 days: 2235 accesses
  • All time: 12431 accesses

Cited by

BioMed Central: 2 citations

Research article   Open Access

Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients

Diana Carmona-Fernandes, Maria Santos, Inês Perpétuo, João Fonseca, Helena Canhão Arthritis Research & Therapy 2011, 13:R175 (25 October 2011)

Abstract | Full text | PDF | PubMed

Review   Free Highly Accessed

The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis

Keith D Brown, Estefania Claudio, Ulrich Siebenlist Arthritis Research & Therapy 2008, 10:212 (21 August 2008)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Google Scholar: View citations

ISI Web of Science: View citations

PubMed Central: View citations